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Abstract word count 251 40 
 41 
Background 42 
Guidelines recommend drug treatment for patients with heart failure with a reduced 43 
ejection fraction (HFrEF), however the evidence for benefit in patients with mild 44 
disease, such as most in primary care, is uncertain. Importantly drugs commonly 45 
used in heart failure account for one in seven of emergency admissions for adverse 46 
drug reactions. 47 
 48 
Aim 49 
To determine to what extent patients included in studies of heart failure treatment 50 
with beta blockers, ACE inhibitors and aldosterone antagonists were representative 51 
of a typical primary care population with HFrEF in England.  52 
 53 
Design and Setting 54 
Systematic review of RCTs of drug treatment in patients with HFrEF. 55 
 56 
Method 57 
MEDLINE, MEDLINE In-process, EMBASE, and CENTRAL were searched from 58 
inception to March 2015. We compared the characteristics of the patient’s NYHA 59 
classification with a primary care reference population with HFrEF. 60 
 61 
Results 62 
30 studies were included. Two had incomplete data. None had a ‘close match’ 63 
(<10% deviation from reference study) for NYHA class I disease, 5/28were a close 64 
match for NYHA class II, 5/28 for NYHA class III, and 18/28 for NYHA class IV. In 65 
general, pre-existing cardiovascular conditions, risk factors and comorbidities were 66 
representative of the reference population.  67 
 68 
Conclusion 69 
Patients recruited to studies typically had more severe heart failure than the 70 
reference primary care population. When evidence from sicker patients is 71 
generalised to less sick people, there is increased uncertainty about benefit and also 72 
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a risk of harm from overtreatment. More evidence is needed on the effectiveness of 73 
treatment of heart failure in asymptomatic patients with NYHA class 1. 74 
 75 
Keywords: heart failure, drug treatment, primary health care, guidelines 76 
 77 
 78 
How this fits in 79 
Heart failure is common in primary care and carries a high morbidity and mortality 80 
which is associated with the degree of failure; beta blockers, ACE/ARB and 81 
aldosterone antagonists have all been shown to reduce mortality and morbidity, but 82 
also carry a significant risk of ADRs. We have shown that patients with heart failure 83 
in primary care tend to have mild heart failure, but the evidence for effectiveness for 84 
these drugs comes from a population with more severe heart failure. More evidence 85 
is needed for the effectiveness of these treatments in populations typical of primary 86 
care. 87 
 88 
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 100 
 101 
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Introduction  104 
 105 
Heart failure with reduced ejection fraction (HFrEF) is a common chronic, debilitating 106 
disease which has a prevalence of 0.7% and affects 400,000 adults in the United 107 
Kingdom (UK) (1). The annual cost of heart failure to the NHS is around 2% of its 108 
total budget, and approximately 70% of this total is due to the costs of hospitalisation 109 
(2). There is a large variation in clinical presentation of heart failure with some 110 
patients having no symptoms at the time of diagnosis, whereas others have 111 
significant morbidity. The diagnosis is made based on the presence of signs and 112 
symptoms of heart failure and through the use of echocardiography to measure left 113 
ventricular ejection fraction (LVEF) ejection fraction (3). A LVEF less than 40% 114 
confirms a diagnosis of HFrEF, which has been extensively studied in the literature. 115 
 116 
Symptoms of heart failure can be graded using the New York Heart Association 117 
(NYHA) functional classification into one of four categories (Table 2) (4). In one study 118 
of UK primary care patients with HFrEF, 47% had no symptoms (grade I), 36% had 119 
mild symptoms (grade II), 7% had moderate symptoms (grade III), and 10% had 120 
severe symptoms (grade IV) (5). Mortality rates from heart failure are high, one UK 121 
cohort study reported that 14% (95% C.I. 11% to 18%) of patients died within 6 122 
months of diagnosis (6). Patients with higher NYHA symptom scores have a worse 123 
prognosis although even patients with mild heart failure have higher mortality (7). 124 
 125 
Several large trials have found a reduction in mortality and hospitalisation in patients 126 
with systolic heart failure following treatment with beta blockers, ACE (angiotensin 127 
converting enzyme) inhibitors and aldosterone antagonists (8, 9). These drugs have 128 
also been shown to be cost effective for the treatment of heart failure (10). This 129 
evidence has led to guideline recommendations adopting these treatments for 130 
systolic heart failure across the world (2, 7, 11, 12). The National Institute for Health 131 
and Care Excellence (NICE) heart failure guideline recommends that all primary care 132 
patients with systolic heart failure should be offered beta blockers and ACE inhibitors 133 
regardless of NYHA class. This indicator is supported by evidence generalized from 134 
higher risk populations (NYHA grades III–IV), in which there is clear evidence of 135 
5 
 
benefit for beta blockers and ACE inhibitors, however the evidence of benefit in 136 
lower risk populations is more equivocal (13, 14). 137 
 138 
The applicability of guideline recommendations for management of diseases 139 
(including heart failure) in primary care has recently been questioned as this 140 
research is rarely conducted in representative populations (13). This question is 141 
important in heart failure because the effectiveness of treatment may depend on the 142 
severity of disease, and beta blockers and ACE inhibitors carry significant morbidity 143 
risk, and account for approximately one in seven emergency hospital admissions 144 
due to adverse drug reactions (15).  145 
 146 
The aim of our study was to determine to what extent patients included in studies of 147 
heart failure treatment with beta blockers, ACE inhibitors and aldosterone 148 
antagonists were representative of the NYHA class and other characteristics of a 149 
typical primary care population with heart failure in England.  150 
 151 
 152 
 153 
 154 
 155 
 156 
 157 
 158 
 159 
 160 
 161 
 162 
 163 
 164 
 165 
 166 
 167 
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Methods 168 
 169 
A literature search was undertaken to identify randomised controlled trials of systolic 170 
heart failure drugs. MEDLINE, MEDLINE In-process, EMBASE, and CENTRAL were 171 
searched from inception to March 2015. The search strategy for MEDLINE is shown 172 
in supplementary data Appendix 1 and this was modified for other databases. Titles 173 
and abstracts were screened by two authors independently according to the 174 
following pre-specified inclusion and exclusion criteria.  175 
 176 
Inclusion criteria were randomised controlled trials (RCTs) which included patients 177 
with HFrEF. Intervention drugs included angiotensin-converting enzyme inhibitors 178 
(ACE inhibitors), beta blockers, angiotensin II receptor blockers (ARBs) and 179 
aldosterone antagonists (e.g. spironolactone and eplenerone). There were no 180 
language restrictions. Exclusion criteria were studies with a follow-up of less than six 181 
weeks, those comprising a single-dose regimen, and studies not judged to be 182 
generalizable to a primary care population (such as one study of patients on 183 
dialysis). Disagreements were resolved through discussion or by a third researcher, 184 
and full text articles were retrieved for each abstract meeting these criteria. 185 
 186 
Data were extracted from each included study into a template which included study 187 
design, intervention, inclusion and exclusion criteria, baseline characteristics, 188 
primary outcome and mortality data. Data extraction was checked by a second 189 
researcher and any disagreements were resolved through discussion or by a third 190 
researcher. Authors were contacted for individual level data. No authors shared 191 
individual level data and our difficulties accessing these data have been described 192 
elsewhere (16). Study exclusion was guided by pre-defined exclusion criteria as 193 
described. 194 
 195 
We used data from the largest study on the prevalence of heart failure in the UK (the 196 
Echocardiographic Heart Study of England Screening (EHES)) study (5). This study 197 
randomly selected a large population of 6286 people aged 45 years and over, and 198 
was the best fit to an English population of five studies of heart failure prevalence 199 
that we identified (17, 18, and 19). The EHES study had a high participation rate of 200 
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63% (3960 patients) and wide geographical spread of populations which was 201 
representative of inner-city, urban, suburban, and rural communities. The EHES 202 
study was used as the ‘reference population’ throughout this study. 203 
 204 
For each study we analysed the NYHA class, baseline cardiovascular risk factors, 205 
baseline cardiovascular comorbidities and use of heart failure drugs. These 206 
outcomes were compared between the reference study and each extracted study. 207 
Each patient-specific variable was compared to the reference study in terms of 208 
prevalence or frequency of use. To allow quantification of similarity between the 209 
selected study population and the reference study population, we assessed the 210 
percentage deviation and allocated this as being a ‘close match’, ‘fair match’ or ‘poor 211 
match’. If the extracted study population had a ≤10% deviation from the reference 212 
study, it was termed as a ‘close match’, if the deviation was 11-20%, it was termed a 213 
‘fair match’, and if the deviation was >20%, it was termed a ‘poor match’. These 214 
parameters were set-out a priori. For example, if a study reported 10% class 1, 25% 215 
class 2, 40% class 3 and 25% class 4, to assess close match we applied a 10% 216 
absolute deviation (i.e. 0-20%, 15-35%, 30-50% and 15-35% respectively) and 217 
compared it to classes in the reference population (47%, 36%, 7% and 10% 218 
respectively), we have shown this worked example in the table 1. For each of the 219 
appendices, the studies were organised in descending order according to the 220 
similarity or ‘closeness of match’ they shared with the reference population. 221 
 222 
 223 
Results 224 
 225 
Literature searching identified 6785 studies, 4433 after de-duplication (Figure 1). 226 
Thirty RCTs met the inclusion criteria, representing 43,454 patients with HFrEF. 227 
Characteristics of included studies are shown in Table 3. Of the included studies, 13 228 
investigated beta-blockers, 8 ACE-inhibitors, 6 ARBs and 4 spironolactone. One 229 
study compared ACEi and ARBs (ELITE I, 2000). Of the 30 extrapolated studies, 230 
sample size ranged from 59 – 5010 participants. Follow up ranged from 3 – 73 231 
months.  232 
 233 
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The reference population is shown in Table 4. The overall mean age was 69 years, 234 
and was 81% male. Most patients had NYHA class 1 (47%) and only 17% of patients 235 
had class 3 or 4. 236 
 237 
NYHA class 238 
Table 5 shows heart failure RCTs compared to the reference population, stratified by 239 
NYHA class. 28/30 studies had complete data on NYHA classes. None of the studies 240 
had a ‘close match’ (green bar) for NYHA class I disease, 3/28 (11%) displayed a 241 
‘fair match’ (amber bar), and 25/28 (89%) a ‘poor match’ (red bar). For NYHA class II 242 
5/28 (18%) studies has a ‘close match’, 9/28 (31%) a ‘fair match’ and 14/28 (48%) a 243 
‘poor match’. For NYHA class III, 5/28 (18%) displayed a ‘close match’, 3/28 (11%) a 244 
‘fair match’, and 20/28 (71%) a ‘poor match’. For NYHA class IV, 18/28 (64%), 245 
displayed a ‘close match’, and 7/28 (25%) had a ‘poor match’. 246 
 247 
Baseline cardiovascular risk factors 248 
Cardiovascular risk factors were largely representative of the reference population 249 
(supplementary data Appendix 2). 25/30 (83%) of the studies had a ‘close match’ to 250 
the age of the reference population, which was a mean of 69 years. 19/30 studies 251 
(63%), had a ‘close match’ with the proportion of the reference population who were 252 
male, which was 81%. The majority of extracted studies, 20/30 (67%), did not 253 
present ethnicity data. Of those that did, 7/10 (70%) had a ‘close match’ and 3/10 254 
(30%) had a ‘poor match’ with the reference population which was 97% white. 23/30 255 
(77%) extracted studies did not present smoking status data. Of the 7 that did, 1/7 256 
(14%) had a ‘fair match’ and 6/7 (86%) a ‘poor match’ to the reference population of 257 
whom 69% were smokers. A family history of premature myocardial infarction was 258 
not reported in any of the studies. 259 
 260 
Baseline cardiovascular comorbidities  261 
The majority of the studies, 23/30 (77%), reported the presence of pre-existing 262 
angina but 13/30 (43%) studies did not report the presence of previous myocardial 263 
infarction, pre-existing hypertension, or diabetes mellitus (supplementary data 264 
Appendix 3). In general, pre-existing cardiovascular conditions recorded in the 265 
extracted studies were representative of the reference population. When comparing 266 
for the presence of pre-existing myocardial infarction, 10/17 (59%) of the extracted 267 
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studies had a ‘close match’, 6/17 (35%) had a ‘fair match’ and 1/17 (6%) had a ‘poor 268 
match’ to the reference population which reported a prevalence of 53%. A similar 269 
trend was noted for hypertension, of which, 7/17 (41%) of the extracted studies had 270 
a ‘close match’, 3/17 (18%) had a ‘fair match’ and 7/17 (41%) had a ‘poor match’ to 271 
the reference population (reported prevalence, 39%).  272 
 273 
For diabetes mellitus 7/17 (41%) of the extracted studies had a ‘close match’, 6/17 274 
(35%) had a ‘fair match’ and 4/17 (26%) had a ‘poor match’ to the reference 275 
population (reported prevalence, 15%). As mentioned, the presence of angina was 276 
recorded in only seven studies. Of which, 3/7 (43%) had a ‘close match’, 3/7 (43%) 277 
had a ‘fair match’ and 1/7 (14%) had a ‘poor match’ to the reference population 278 
(reference population reported prevalence, 36%).  279 
 280 
Use of heart failure drugs. 281 
The use of important heart failure drugs varied significantly across the analysed 282 
studies (supplementary data Appendix 4). 20/30 (67%) studies did not report data on 283 
the use of aspirin. Of the remaining 10, 5/10 (50%) had a ‘close match’, 4/10 (40%) a 284 
‘fair match’, and 1/10 (10%) had a ‘poor match’ to the reference population of whom 285 
53% took regular aspirin.  286 
 287 
22/30 (73%) of extracted studies did not report data on the use of calcium channel 288 
blockers (CCBs). Of the remaining 8, 4 (50%) had a ‘close match’ and 4 (50%) had a 289 
‘fair match’ to the reference population (which reported CCB usage in 21%).  290 
 291 
A large proportion of the extracted studies investigated beta-blockers and ACE 292 
inhibitors directly, and therefore not assessed for prevalence of use of these 293 
therapies compared to the reference population. Of the 18 studies which did not 294 
study beta-blockers, 11 studies did report data on the proportion of patients using 295 
beta-blockers, and only 3 (27%) had a ‘close match’ to the reference population 296 
(reference population reported frequency, 13%).  297 
 298 
Of the 22 studies that did not directly study ACE inhibitors, 8 studies (36%) did not 299 
report prevalence of use. Therefore only 14 (47%) could be assessed for ACE 300 
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inhibitors, all of which had a ‘poor match’ to the reference population (reference 301 
population reported frequency, 26%).  302 
 303 
11/30 (37%) studies did not report data on the proportion of patients using digoxin; of 304 
the remaining 19, 2 (11%) had a ‘close match’, 2 (11%) had a ‘fair match’ and 15 305 
(79%) had a ‘poor match’ to the reference population (reference population reported 306 
frequency, 7%).  307 
 308 
Spironolactone and eplenerone were the study drug in 4/30 studies and these were 309 
therefore not assessed for similarity to the reference population. Of the remaining 26 310 
studies that did not directly investigate these agents, 10 (39%) did not report 311 
prevalence of use data. As such, only 16 studies could be assessed for 312 
spironolactone and eplenerone use, all of which had a ‘poor match’ to the reference 313 
population (reference population reported frequency, 36%).  314 
 315 
We examined the six studies that were a close match for NYHA class II participants 316 
for evidence of benefit for this class.  Only one study (MERIT) reported outcomes by 317 
NYHA class II (20), the remaining studies reported pooled outcomes for all NYHA 318 
classes. MERIT reported no significant mortality reduction, but a reduction in 2 out of 319 
4 secondary outcomes (development of CHF and hospitalisations).  320 
 321 
 322 
 323 
 324 
Discussion 325 
 326 
Summary 327 
83% of the reference population representing a primary care population with HFrEF 328 
had mild symptoms in NYHA class I and II, however none of the 30 studies were 329 
matched closely with NYHA class 1, and only 5/28 (18%) studies were a ‘close 330 
match’ with NYHA class II symptoms. For patient characteristics of age, sex, 331 
ethnicity, previous MI, hypertension, diabetes and angina; > 40% studies were 332 
closely matched to the reference population. For patient characteristics of smoking 333 
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status, family history of premature heart disease, and the use of beta blockers, ACE 334 
inhibitors and the aldosterone antagonists spironolactone and eplenerone; <30% of 335 
studies were closely matched to the reference population. In this way, we have 336 
shown that these studies are not typically representative of the primary care 337 
population in England, with patients with more severe heart failure being over-338 
represented. 339 
 340 
Strengths and limitations 341 
This study is the first systematic review to determine whether the types of patients 342 
included in studies of treatments for HFrEF were representative of a typical primary 343 
care population with HFrEF in England. We used a large study as the reference 344 
population (5) which randomly selected and screened the population for HFrEF and 345 
our systematic review method was robust. Whist this cohort study was published 15 346 
years ago and the characteristics of the primary care population and treatments have 347 
changed, it is closer to the time when the included RCTs were undertaken. We had 348 
initially intended to obtain individual level data for each NYHA class from each of the 349 
30 identified studies; however, we faced obstacles in terms of non-disclosure of 350 
further information from authors, who either failed to reply to repeated attempts to 351 
make contact or were unwilling for us to access their trial data (16). There may be 352 
some overlap between classes, such as class 1 and 2, which may have led to 353 
misclassification in either the reference study or the included trials. We only included 354 
trials which recruited patients with heart failure, there is a possibility that some trials 355 
with a subgroup of patients with heart failure may not have been identified. 356 
 357 
Comparison with existing literature 358 
This study concurs with the findings of Steel et al, who reported that out of 48 studies 359 
cited in the NICE guidance on heart failure treatment, 43 (90%) were studies of 360 
uncertain relevance to patients in primary care (14). These findings are particularly 361 
important as there is evidence that of heart failure treatments may be less effective 362 
in patients with less severe heart failure (16, 21, 22), and these drugs do account for 363 
significant morbidity. 364 
 365 
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Implications for research and/or practice 366 
The underrepresentation of patients with HFrEF and mild or absent symptoms in 367 
clinical trials has implications for general practitioners who should weigh the potential 368 
benefits of initiating treatment in those with absent or mild symptoms against the 369 
risks of an adverse drug reaction which are significant, although all degrees of heart 370 
failure have raised mortality and morbidity. By extrapolating data from studies of 371 
patients with more severe disease, patients and clinicians may misinterpret the 372 
potential benefits and risks. It is important that the risks and benefits are stratified by 373 
NYHA disease class. 374 
 375 
More studies are needed using individual patient data analysis by heart failure 376 
severity, as most of the outcomes in the current studies were not reported by NYHA 377 
class. This should be complimented by observational studies using, for example, the 378 
CRPD dataset which primarily recruit from primary, rather than secondary care. 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
 389 
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Figure 1: PRISMA diagram  562 
  563 
Records identified through 
database searching  
(n = 6785) 
Sc
re
en
in
g 
In
cl
ud
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fic
at
io
n 
Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed  
(n = 4433) 
Records screened  
(n = 4433) 
Records excluded  
(n = 4365) 
Full-text articles 
assessed for eligibility  
(n = 68) 
Full-text articles excluded 
(n = 38) 
Studies included in 
qualitative synthesis  
(n = 30) 
18 
 
Table 1: Example assessment of an extracted paper compared to the reference 564 
population 565 
 class 1 class 2 class 3 class 4 
Reference 
population (%) 
47 36 7 10 
Extracted study 
(%) 
10 25 40 25 
Extracted study 
with 10% 
deviation (%) 
0-20 15-35 30-50 15-35 
Closeness of 
match (%) 
>20% 11-20% >20 11-20% 
Closeness of 
match (label) 
poor fair poor fair 
 566 
 567 
Table 2: New York Heart Association classes of heart failure (4). 568 
Class Patient Symptoms 
I 
No limitation of physical activity. Ordinary physical activity 
does not cause undue fatigue, palpitation, dyspnoea 
(shortness of breath). 
II 
Slight limitation of physical activity. Comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, 
dyspnoea (shortness of breath). 
III 
Marked limitation of physical activity. Comfortable at rest. 
Less than ordinary activity causes fatigue, palpitation, or 
dyspnoea. 
IV 
Unable to carry on any physical activity without discomfort. 
Symptoms of heart failure at rest.  If any physical activity is 
undertaken, discomfort increases. 
Table 3: Characteristics of included studies (References: 23-51) 569 
Study ID Comparison Number of 
participants
Primary outcome Follow up 
19 
 
AREA-CHF 
2009 
Canrenon 
Placebo 
231 
236 
Change in LV diastolic volume 12 months 
BEST 2003 Bucindolol 
Placebo 
114 
112 
Death and heart failure 
hospitalisation composite 
19 months 
Borghi 2013 Ramipril  
Zofenopril 
73 
102 
Survival 73+/-14 
months 
CARNEBI 
2013 
Carvedilol 
Bisoprolol 
Nebivolol 
61 
crossover 
NYHA class, biochemistry and 
physiological testing 
6 months 
(2 x 3 
crossover) 
CELICARD 
2000 
Celiprolol 
Placebo 
62 
62 
Functional score - Goldman 
score 
12 months 
CHARM 
Added 2003 
Candesartan 
Placebo 
1011 
1014 
Cardiovascular death or 
unplanned hospital admissions 
for worsening CHF
34 months 
CHARM 
Alterative 
2003 
Candesartan 
Placebo 
1273 
1271 
Cardiovascular death or 
unplanned hospital admissions 
for worsening CHF 
41 months 
CIBIS 1994 Bisoprolol 
Placebo 
320 
321 
All-cause mortality 23 months 
CIBIS 1999 Bisoprolol 
Placebo 
1327 
1320 
All-cause mortality 16 months 
Cicoira 2002 Spironolactone 
Placebo 
54 
52 
Physiological/functional 
improvement 
12 months 
Cohn 2001 Valsartan 
Placebo 
2511 
2499 
All-cause mortality and 
combined mortality and 
morbidity 
23 months 
Colucci 1996 Carvedilol 
Placebo 
232 
134 
Disease progression and 
death composite 
12 months 
COMET 
2003 
Carvedilol 
Metoprolol 
1511 
1518 
All-cause mortality 58 months 
Dalla-Volta 
1999 
Delapril 
Enalapril 
88 
91 
Physiological/functional 
improvement 
12 months 
ELITE II 
2000 
Losartan 
Captopril 
1578 
1574 
All-cause mortality 18 months 
Kum 2008 Add on 
Irbesartan 
Placebo 
50 
50 
6MHW, Minnesota (QoL), peak 
exercise capacity on treadmill 
12 months 
Liu 2014 Metoprolol 
Conventional 
therapy 
77 
77 
NYHA class, LVESD, LVEDD, 
LVEF, 6-min walking distance, 
medication safety 
6 months 
MAIN CHF II 
2014 
Bisoprolol 
Carvedilol 
21 
14 
Clinical and functional status, 
mortality rate 
8 months 
MERIT-HF 
1999 
Metoprolol CR 
Placebo 
1990 
2001 
All-cause mortality 12 months 
Munich 1991 Captopril 
Placebo 
83 
87 
Cardiovascular-cause mortality 33 months 
Pitt 1999 Spironolactone 
Placebo 
822 
841 
All-cause mortality 24 months 
Rieger 1999 Candesartan 
4mg 
Candesartan 
8mg 
Candesartan 
16mg 
211 
208 
212 
213 
Increase in exercise tolerance, 
reduction in NYHA class 
3 months 
20 
 
Placebo 
SENIORS 
2005 
Nevovitol 
Placebo 
1067 
1061 
All-cause mortality and time to 
first CVD admission 
21 months 
SOLVD 1991 Enalapril 
Placebo 
1285 
1284 
Clinical and functional status, 
mortality rate 
41.4 
months 
SOLVD 1992 Enalapril 
Placebo 
2111 
2117 
Clinical and functional status, 
mortality rate 
37.4 
months 
Sturm 2000 Atenolol 
Placebo 
51 
49 
Worsening heart failure or 
death 
24 months 
US 
Carvedilol 
2001 
Carvedilol 
Placebo 
Black: 127,  
Not Black: 
569 
Black:90,  
Not Black: 
308  
Ethnicity (self-reported), 
ejection fraction, clinical status 
and major clinical events 
15 months 
Yodfat 1991 Captopril 
Placebo 
41 
43 
Functional status 3 months 
Zannad 1998 Fosinopril 
Placebo 
122 
132 
Cardiovascular mortality and 
event-free survival 
12 months 
Zannad 2011 Eplenerone 
Placebo 
1364 
1373 
Cardiovascular mortality and 
event-free survival 
21 months 
 570 
Abbreviations: 6MHW: 6-Minute Hall Walk, AREA-CHF: Anti-remodelling effect of canrenone 571 
in patients with mild chronic heart failure, BEST: Beta-Blocker Evaluation in Survival Trial, 572 
CARNEBI: Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in 573 
moderate heart failure, CELICARD: Treatment of heart failure with celiprolol, a 574 
cardioselective beta blocker with beta-2 agonist vasodilatory properties, CHARM: 575 
Candesartan in Heart failure - Assessment of moRtality and Morbidity, CHF: Congestive 576 
Heart Failure, CIBIS: Cardiac Insufficiency Bisoprolol Study, COMET: Carvedilol Or 577 
Metoprolol European Trial, CVD: Cardiovascular Disease, ELITE: Evaluation of Losartan in 578 
the Elderly, LV: Left Ventricle , LVEDD: Left Ventricular End-Diastolic Diameter, LVEF: left 579 
Ventricular Ejection Fraction, LVESD: Left Ventricular End-Systolic Diameter, MAIN CHF: 580 
Multistep Administration of bisoprolol IN Chronic Heart Failure, MERIT-HF: Metoprolol 581 
CR/XL Randomized Intervention Trial in Congestive Heart Failure, NYHA: New York Heart 582 
Association, SENIORS: Randomized trial to determine the effect of nebivolol on mortality 583 
and cardiovascular hospital admission in elderly patients with heart failure, SOLVD: Studies 584 
of Left Ventricular Dysfunction 585 
 586 
 587 
 588 
 589 
 590 
  591 
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Table 4: Summary of the ejection fraction <40% cohort for the reference population: 592 
‘Prevalence of left-ventricular systolic dysfunction and heart failure in the 593 
Echocardiographic Heart of England Screening (EHES) study: a population based 594 
study’. 595 
 596 
Characteristic Total (n=72)   
Age, mean in year (SD) 69 (9)   
Women 14 (19%)   
Men 58 (81%)   
Ever smoked 50 (69%)   
Non-white 105 (3%)   
Any electrocardiogram abnormality 2 (3%)   
Height, mean in metres (SD) 1·71 (0·09)   
Weight, mean in kilograms (SD) 80.8 (14·6)   
Heart rate, mean in beats per min (SD) 77.3 (17.8)   
Forced expiratory volume at 1 s, mean in litres 
(SD) 2·11 (0·76)   
Forced vital capacity, mean in litres (SD) 2·55 (0·85)   
Systolic blood pressure, mean in mmHg (SD) 148·4 (21·1)   
Diastolic blood pressure, mean in mmHg (SD) 87.1 (12.3)   
New York Heart Association class
1 34 (47%)   
2 26 (36%)   
3 5 (7%)   
4 7 (10%)   
History 
Myocardial ischaemia 38 (53%)   
Angina 26 (36%)   
Hypertension 28 (39%)   
Diabetes 11 (15%)   
Family myocardial ischaemia (age <65 years) 25 (35%)   
Medication taken 
ACE Inhibitors 19 (26%)   
Diuretics 26 (36%)   
β-blockers 9 (13%)   
Calcium antagonists 15 (21%)   
Aspirin 38 (53%)   
Digoxin 5 (7%)   
 597 
 598 
 599 
 600 
 601 
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 602 
Table 5: NYHA classification in heart failure RCTs compared to the reference 603 
population. 604 
 NYHA Class (% of ‘reference population’) 
(Reference 5, Davies et al, 2001). 
 
Heart Failure 
RCTs 
N-value
I (47%) II (36%) III (7%) IV (10%) 
SOLVD 1992 4228 11-20% <10% <10% <10%  
Munich 1991 170 11-20% 11-20% 11-20% <10%  
Borghi 2013 175 11-20% 11-20% 11-20% <10%  
US Carvedilol 1996 1094 >20% <10% >20% <10%  
Liu 2014 154 >20% <10% >20% <10%  
CHARM Added 
2003 
2548 
>20% <10% >20% <10% 
 
MERIT-HF 1999 3991 >20% <10% >20% <10%  
Zannad 1998 254 >20% >20% <10% <10%  
CELICARD 2000 124 >20% 11-20% >20% <10%  
CHARM Alterative 
2003  
2028 
>20% 11-20% >20% <10% 
 
SENIORS 2005 2128 >20% 11-20% >20% <10%  
SOLVD 1991 2569 >20% 11-20% >20% <10%  
COMET 2003 3029 >20% 11-20% >20% <10%  
Cicoira 2002 106      
CARNEBI 2013 183 >20% >20% <10% >20%  
MAIN CHF II 2014 59 >20% >20% <10% >20%  
Colucci 1996 366 >20% >20% <10% >20%  
Zannad 2011 2737 >20% >20% >20% <10%  
Sturm 2000 100 >20% >20% >20% <10%  
Cohn 2001 5010 >20% >20% >20% <10%  
CIBIS 1994 641 >20% >20% >20% <10%  
CIBIS 1999 2647 >20% >20% >20% <10%  
ELITE II 2000 3152 >20% 11-20% >20% >20%  
Kum 2008 100 >20% 11-20% >20% >20%  
Rieger 1999 844 >20% >20% 11-20% >20%  
BEST 2003 226 >20% >20% >20% >20%  
Dalla-Volta 1999 179 >20% >20% >20% >20%  
AREA-CHF 2009 382 >20% >20% >20% >20%  
Pitt 1999 1663 >20% >20% >20% >20%  
Yodfat 1991 84  
      
 <10% deviation from reference study  
 11-20% deviation from reference study 
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Supplementary data 611 
 612 
Appendix 1: MEDLINE search strategy 613 
 614 
1. randomized controlled trial.pt. 615 
2. controlled clinical trial.pt. 616 
3. randomized.ab. 617 
4. placebo.ab. 618 
5. clinical trials as topic.sh. 619 
6. randomly.ab. 620 
7. trial.ti. 621 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7 622 
9. exp animals/ not humans.sh. 623 
10. 8 not 9 624 
11. exp angiotensin-converting enzyme inhibitors/ 625 
12. angiotensin-converting enzyme inhibitor$.mp.  626 
13. exp enalapril/ 627 
14. (alacepril or altiopril or benazepril or captopril or ceronapril or cilazapril or delapril 628 
or derapril or  enalapril or fosinopril or idapril or imidapril or lisinopril or moexipril or 629 
moveltipril or pentopril or perindopril or quinapril or ramipril or spirapril or temocapril 630 
or trandolapril or zofenopril).mp. 631 
15. 11 or 12 or 13 or 14 or 15  632 
16.  exp adrenergic beta-antagonists/ 633 
17. (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or 634 
atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or 635 
bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or 636 
bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or 637 
carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or 638 
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or 639 
dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or 640 
flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or 641 
hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or 642 
isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or 643 
mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or 644 
nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or 645 
nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol 646 
or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or 647 
ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol 648 
or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or 649 
xibenolol).mp. 650 
 >20% deviation from reference study 
 Insufficient information to calculate deviation 
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18. (beta adj2 (antagonist? or receptor? or adrenergic? block$)).tw. 651 
19. adrenergic beta antagonist?.tw. 652 
20. 16 or 17 or 18 or 19 653 
21. exp angiotensin II type 1 receptor blockers/ 654 
22. exp losartan/ 655 
23. (angiotensin receptor blocker$ or angiotensin II receptor blocker$ or angiotensin 656 
receptor antagonist$ or angiotensin II receptor antagonist$ or candesartan or 657 
eprosartan or irbesartan or losartan or olmesartan or tasosartan or telmisartan or 658 
valsartan).mp. 659 
24. 18 or 19 or 20 or 21 or 22 or 23 660 
25. exp Heart Failure/ 661 
26. (heart adj2 failure*).tw. 662 
27. (congestive adj2 heart).tw. 663 
28. (cardiac adj2 failure*).tw. 664 
29. (myocardial adj2 failure*).tw. 665 
30. 25 or 26 or 27 or 28 or 29 666 
31. 10 and 30 and 15 667 
32. 10 and 30 and 20 668 
33. 10 and 30 and 24 669 
34. 31 or 32 or 33 670 
35. 34 and 2005:2012.(sa_year). 671 
36. remove duplicates from 35 672 
 673 
 674 
 675 
 676 
 677 
 678 
 679 
 680 
 681 
 682 
 683 
 684 
 685 
 686 
 687 
 688 
 689 
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 695 
Appendix 2: Prevalence of CVD risk factors in heart failure RCTs compared to the 696 
reference population 697 
CVD Risk Factors (% of ‘reference population’)  
(Reference 5, Davies et al, 2001). 
Heart Failure 
RCTs 
N-
value Age (69+/-
9yrs) 
Male 
(81%) 
White 
(97%) 
Smoker 
(69%) 
FH of 
MI< 
65(35
%) 
CHARM Added 
2003 
2548 
<10% <10% <10% 11-20% 
SOLVD 1992 4228 <10% <10% <10% >20% 
Pitt 1999 1663 <10% <10% <10% 
MERIT-HF 1999 3991 <10% <10% <10% 
CHARM Alterative 
2003  
2028 
<10% 11-20% <10% >20% 
Borghi 2013 175 <10% 11-20% <10% >20% 
SOLVD 1991 2569 <10% <10% 11-20% >20% 
Zannad 2011 2737 <10% <10% 11-20% 
Zannad 1998 254 <10% 11-20% <10% 
CARNEBI 2013 183 <10% <10%
US Carvedilol 1996 1094 <10% <10% 
COMET 2003 3029 <10% <10% 
Munich 1991 170 <10% <10% 
Cohn 2001 5010 <10% <10% 
CIBIS 1994 641 <10% <10% 
CIBIS 1999 2647 <10% <10% 
AREA-CHF 2009 382 <10% <10% 
ELITE II 2000 3152 <10% 11-20% 11-20% 
SENIORS 2005 2128 <10% 11-20% >20% 
BEST 2003 226 11-20% <10% >20% 
Rieger 1999 844 <10% 11-20% 
MAIN CHF II 2014 59 <10% 11-20% 
Liu 2014 154 <10% 11-20% 
Kum 2008 100 <10% 11-20% 
Dalla-Volta 1999 179 11-20% <10% 
Sturm 2000 100 11-20% <10% 
Colucci 1996 366 11-20% <10% 
CELICARD 2000 124 11-20% <10% 
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 709 
Appendix 4: Use of heart failure drugs in heart failure RCTs compared to the 710 
reference population 711 
   
   Heart Failure Drugs (% of ‘reference 
population’) (Davies et al, 2001). 
Heart Failure 
RCTs 
Study Drugs Number of 
Participants 
Aspirin 
(53%) 
CCBs 
(21%) 
B-
blockers 
(13%) 
Digoxi
n (7%) 
ACEi 
(26%) 
ELITE II 2000 Losartan, 
Captopril 
3152 <10% <10% <10%   
Rieger 1999 Candesartan, 
Placebo 
844 <10%  11-20% >20% >20% 
SOLVD 1992 Enalapril, 
Placebo 
4228  11-20% 11-20% <10%  
CHARM 
Alternative 2003 
Candesartan, 
Placebo 
2028 <10%  >20% >20%  
CHARM Added 
2003 
Candesartan, 
Placebo 
2548 <10%  >20% >20% >20% 
SENIORS 2005 Nebivolol, 
Placebo 
2128 11-20% <10%  >20% >20% 
Pitt 1999 Spironolactone, 
Placebo 
1663 11-20%  <10% >20% >20% 
SOLVD 1991 Enalapril, 
Placebo 
2569  11-20% <10% >20%  
Kum 2008 Irbesartan add-
on, Current 
drugs 
100 11-20%  >20% <10%  
AREA-CHF 
2009 
Canrenone, 
Placebo 
382  11-20% >20% 11-20% >20% 
MERIT-HF 1999 Metoprolol 
CR/XL, Placebo 
3991 <10%   >20% >20% 
COMET 2003 Carvedilol, 
Metoprolol 
3029 11-20%   >20% >20% 
Zannad 2011 Eplenerone, 
Placebo 
2737   >20% 11-20% >20% 
Sturm 2000 Atenolol, 
Placebo 
100 >20%   >20% >20% 
Cohn 2001 Valsartan, 
Placebo 
5010   >20% >20% >20% 
CIBIS 1994 Bisoprolol, 
Placebo  
641    >20% >20% 
CIBIS 1999 Bisoprolol, 
Placebo 
2647    >20% >20% 
BEST 2003 Bucindolol, 
Placebo 
226    >20% >20% 
Zannad 1998 Fosinopril, 
Enalapril 
254    >20%  
CARNEBI 2013 Carvedilol, 
Nebivolol, 
Bisoprolol 
183     >20% 
Liu 2014 Metoprolol, 
Routine 
treatment 
154      
28 
 
Dalla-Volta 1999 Delapril, 
Enalapril 
179      
Munich 1991 Captopril, 
Placebo 
170      
Colucci 1996 Carvedilol, 
Placebo, 
366      
CELICARD 
2000 
Celiprolol, 
Placebo 
124      
MAIN CHF II 
2014 
Bisoprolol, 
Carvedilol 
59      
US Carvedilol 
1996 
Carvedilol, 
Placebo 
1094      
Yodfat 1991 Captopril, 
Placebo 
84      
Borghi 2013 Zofenopril, 
ramipril 
175      
Cicoira 2002 Spironolactone, 
Placebo  
106      
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 720 
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 <10% deviation from reference study  
 11-20% deviation from reference study 
 >20% deviation from reference study 
 Insufficient information to calculate deviation 
 Drug investigated and therefore not assessed 
